Vancouver biotech Zymeworks rejects $10.50-a- share hostile bid from Dubai hedge fund All Blue

Retrieved on: 2022-05-20 20:24:30

Tags for this article:

Click the tags to see associated articles and topics

Vancouver biotech Zymeworks rejects $10.50-a- share hostile bid from Dubai hedge fund All Blue. View article details on hiswai:

Excerpt

Vancouver biotech Zymeworks rejects $10.50-a- share hostile bid from Dubai hedge fund All Blue. Sean Silcoff Technology Reporter.

Article found on: www.theglobeandmail.com